571 results on '"Body, J.-J."'
Search Results
2. Distribution of Fracture Sites in Postmenopausal Overweight and Obese Women: The FRISBEE Study
3. MOF/Hip Fracture Ratio in a Belgian Cohort of Post-menopausal Women (FRISBEE): Potential Impact on the FRAX® Score
4. Risk factors for imminent fractures: a substudy of the FRISBEE cohort
5. Bone health in cancer: ESMO Clinical Practice Guidelines
6. Osteoporosis treatment gap in a prospective cohort of volunteer women
7. Bone management in hematologic stem cell transplant recipients
8. Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells
9. A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement
10. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
11. Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club
12. The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club
13. Переваги та ризики позаскелетної дії кальцію, вітаміну D та антиостеопоротичних препаратів
14. Therapie der tumorinduzierten Hyperkalzämie und der tumorinduzierten Osteolyse
15. Therapie der tumorinduzierten Hyperkalzämie
16. Impact of non-hip fractures in elderly women: a narrative review
17. Cancer-associated bone disease
18. Prevention and treatment of side-effects of systemic treatment: bone loss
19. Heterogeneity of Metabolic Response to Systemic Therapy in Metastatic Breast Cancer Patients
20. Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence
21. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper
22. Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
23. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club
24. Practical guidance for the management of aromatase inhibitor-associated bone loss
25. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club
26. Bone health in cancer patients: ESMO Clinical Practice Guidelines†
27. Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club
28. Impact of non-hip fractures in elderly women: a narrative review.
29. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club
30. The Use of Bone Markers in a 6-Week Study to Assess the Efficacy of Oral Clodronate in Patients with Metastatic Bone Disease
31. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis
32. Bone health in cancer: ESMO Clinical Practice Guidelines †
33. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy
34. Investigation of Bone Disease Using Isomerized and Racemized Fragments of Type I Collagen
35. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts
36. Do Estrogens Effectively Prevent Osteoporosis-Related Fractures?
37. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia
38. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis
39. Assessment of dyspnea in advanced cancer patients
40. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
41. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial
42. Osteoporosis treatment gap in the FRISBEE cohort
43. Eine doppelblind randomisierte Studie zu Denosumab im Vergleich zu Zoledronsäure für die Behandlung von Knochenmetastasen bei Patienten mit Mammakarzinom: Ergebnisse einer randomisierter Phase 3 Studie: PP405
44. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club
45. Regulation of c-fos and c-jun Expression by Calcitonin in Human Breast Cancer Cells
46. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
47. Reply to the article “Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases” by J.-J. Body et al. (Ann Oncol 2007; 18: 1165–1171)
48. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review
49. Bleeding in advanced cancer patients
50. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.